{"id":11384,"date":"2003-07-01T11:49:57","date_gmt":"2003-07-01T11:49:57","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=11384"},"modified":"2014-05-27T12:23:05","modified_gmt":"2014-05-27T12:23:05","slug":"tenofovir-european-licence-extended-to-include-first-line-therapy","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/11384","title":{"rendered":"Tenofovir European licence extended to include first-line therapy"},"content":{"rendered":"<p><strong>On 27 May 2003 the European Medicines Evaluation Agency granted approval to expand the indication for tenofovir (Viread) to include the drug\u2019s use in treatment-na\u00efve HIV patients in Europe.<\/strong><\/p>\n<p>The Committee for Proprietary Medicinal Products (CPMP), the scientific committee of the EMEA, issued a positive opinion to expand the indication for tenofovir in February 2003. The Commission\u2019s decision is based on 48-week results from Gilead\u2019s Study 903 in 600 treatment-na\u00efve patients infected with HIV, including patients with a high viral load (&gt;100,000 copies\/mL). [See HTB Jan\/Feb 2003]<\/p>\n<p>Tenofovir was first authorised for sale in the European Union in February 2002 for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients experiencing early virological failure.<\/p>\n<p>Source: Gilead Sciences press release<\/p>\n<p>EMEA documents:<br \/>\n<a href=\"http:\/\/www.ema.europa.eu\/humandocs\/Humans\/EPAR\/viread\/viread.htm\">http:\/\/www.ema.europa.eu\/humandocs\/Humans\/EPAR\/viread\/viread.htm<\/a><\/p>\n<p>Gilead press release:<br \/>\n<a href=\"http:\/\/www.gilead.com\/wt\/sec\/pr_1053732734\">http:\/\/www.gilead.com\/wt\/sec\/pr_1053732734<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 27 May 2003 the European Medicines Evaluation Agency granted approval to expand the indication for tenofovir (Viread) to include the drug\u2019s use in treatment-na\u00efve HIV patients in Europe. The Committee for Proprietary Medicinal Products (CPMP), the scientific committee of &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-11384","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/11384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=11384"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/11384\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=11384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=11384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=11384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}